Saturday 17 October 2026
Export NKTX’s income statement to Excel — free account
Nkarta, Inc.
NKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 74.2% and free cash flow fell 29.2%, each against the same quarter a year earlier.
1.80
0.13
−6.74%
Follow NKTX
Nkarta, Inc. (NKTX) P/E ratio
Nkarta, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2019 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTX Nkarta, Inc. | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| MOLN Molecular Partners AG Sponsored ADR compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| CUE Cue Biopharma, Inc. compare | n/m |
| KRRO Korro Bio, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)